Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Post time 2024-4-26 12:40:12

journal：Circulation

Authors：John W. Ostrominski; Muthiah Vaduganathan; Senthil Selvaraj; Brian L. Claggett; Zi Michael Miao; Akshay S. Desai; Pardeep S. Jhund; Mikhail N. Kosiborod; Carolyn S.P. Lam; Silvio E. Inzucchi; Felipe A. Martinez; Rudolf A. de Boer; Adrian F. Hernandez; Sanjiv J. Shah; Magnus Petersson; Anna Maria Langkilde; John J.V. McMurray; Scott D. Solomon

Published date：2023-12-12

DOI：10.1161/circulationaha.123.065254

PDF link：https://www.ahajournals.org/doi/ ... ATIONAHA.123.065254

Article link：http://dx.doi.org/10.1161/circulationaha.123.065254

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2024-4-26 12:40:13

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AHA] Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AHA] Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial